AMLo Biosciences is thrilled to announce a significant funding milestone, having successfully raised $1.6 million to propel the development of its innovative prognostic test for early-stage melanoma. Established in late 2017, AMLo Biosciences is on a mission to enhance patient care by offering a reliable test for AJCC Stage I and II melanoma. This groundbreaking approach aims to accurately assess patients' true risk of disease progression, empowering healthcare providers and patients alike. For those patients classified as low-risk, this test provides crucial reassurance and supports personalized follow-up care. Conversely, identifying those at risk of metastasis enables timely intervention, which can be life-saving. Central to this effort is the company's flagship product, AMBLor®, designed to integrate smoothly into existing diagnostic protocols for clinicians, making it both accessible and efficient.
The funding raised will be instrumental in advancing the research and development of AMBLor®, enabling AMLo Biosciences to refine its technologies and expand clinical validations. The company boasts a founder team with an internationally recognized history of success within the melanoma research community, leveraging expertise in biomarker identification, drug discovery, and biotech entrepreneurship. This latest funding round marks a pivotal step forward in AMLo Biosciences' journey to revolutionize melanoma diagnosis and treatment, ultimately aiming to improve outcomes for patients worldwide. As AMLo continues to innovate and grow, it remains steadfast in its commitment to addressing the critical needs of melanoma patients by providing tools that promote informed healthcare decisions and tailored therapies.
